Using targeted fecal microbiota transplantation to treat irritable bowel syndrome
Official title: Efficacy and Safety of Proteolytic Activity-Guided fecal Microbiota Transplantation for Irritable Bowel Syndrome (PRAGMAT trial)
Funded at Mayo Clinic Rochester · NIH-10773350 · Data updated 2026-11-12
This study is looking at whether a special treatment called fecal microbiota transplantation (FMT) can help people with irritable bowel syndrome (IBS) who started having symptoms after an intestinal infection, by using healthy gut bacteria from carefully chosen donors to improve their gut health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | September 1, 2024 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $316,102 |
| NIH project number | 1R01DK137800-01 |
| Project ID | NIH-10773350 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who have been diagnosed with post-infection irritable bowel syndrome.
✕Less likely to help
Patients with IBS not related to prior intestinal infections or those with other gastrointestinal disorders may not benefit from this research.
What this research studies
This research investigates the use of fecal microbiota transplantation (FMT) to treat patients with irritable bowel syndrome (IBS), particularly those who developed symptoms after an intestinal infection. The study focuses on selecting donors with specific gut microbiota profiles that can help reduce harmful proteolytic activity in patients. By conducting a randomized, double-blind, placebo-controlled trial, the researchers aim to determine the safety and effectiveness of this targeted approach in alleviating IBS symptoms. Patients will receive FMT from carefully screened donors to potentially restore a healthier gut microbiome.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients suffering from post-infection irritable bowel syndrome.
How similar studies have gone: Previous studies have shown promising results with fecal microbiota transplantation in treating various gastrointestinal disorders, indicating potential success for this novel approach.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Grover, Madhusudan — Mayo Clinic Rochester
- Study coordinator: Grover, Madhusudan
Related research
Other NIH-funded projects on the same topics.
-
Proteolytic Activity-Guided Fecal Microbiota Transplant for PI-IBS
A pilot study will test a targeted fecal microbiota transplant to help adults with post-infection irritable bowel syndrome feel better and have fewer GI symptoms.
-
A new way to use gut bacteria transplants for Irritable Bowel Syndrome
This research explores if a special type of fecal microbiota transplant, guided by specific gut enzyme activity, can safely and effectively improve symptoms for adults with Irritable Bowel Syndrome that developed after an infection.
-
Fecal transplant plus fiber to treat graft-versus-host disease after blood stem cell transplant
A study to see if giving fecal transplant along with dietary fiber helps gut health and reduces complications in patients who have received a stem cell transplant and developed graft-versus-host disease.
-
Fecal microbiota transplantation plus immune checkpoint blockers for solid tumors
This project looks at whether changing gut bacteria with fecal transplants can boost how well cancer treatments called immune checkpoint blockers work in people with solid tumors.
-
Fecal transplant treatment for auto-brewery (gut fermentation) syndrome
This project gives capsule fecal microbiota transplants to adults with auto-brewery syndrome to try to stop their gut from producing alcohol and causing unexplained intoxication.
-
How missing gut bacteria may drive post-infection irritable bowel syndrome
This project aims to restore missing gut bacteria in adults with post-infection IBS to reduce harmful protein‑breaking enzymes that may cause gut damage and symptoms.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.